Where could bioengineering and technological advances take drug discovery?
Drug Target Review explores the findings of a recent review of molecular, cellular, multi-cellular and tissue engineering and modelling technologies for drug design.
List view / Grid view
Articles
Inhibiting the epichaperome to combat Alzheimer’s disease
Pre-clinical studies demonstrate that inhibiting the ’epichaperome’ can restore neural networks to normal levels. Dr Barbara Wallner at Samus Therapeutics explains how targeting the epichaperome could work as a potential treatment for Alzheimer’s and other neurodegenerative diseases.
Safer and more affordable medicine for all? How pharmacogenomics may level the playing field
Dr Mike Tocci discusses how pharmacogenomics can revolutionise medical research and improve the efficacy and quality of drugs.
Exploring future spinal cord injury therapies
Drug Target Review explores five of the latest research developments in the field of spinal cord injury (SCI) repair.
Using virtual screening to identify coronavirus treatments
Drug Target Review rounds up the latest updates on research into coronavirus treatments, focusing on virtual screening to find therapies for COVID-19.
Developing an automatic microfluidic platform using ‘ferrobots’
A new microfluidic technology has been developed by researchers, which utilises magnetic ferrobots to automate chemical analyses and assays.
Discovering and designing drugs with artificial intelligence
The first drug designed using artificial intelligence (AI) has moved into its Phase I trial. Professor Andrew Hopkins of Exscientia explains how an algorithm was used to achieve this milestone.
Rebalancing the immune system to treat autoimmune disease
Dr Nicolas Poirier reveals how immunotherapies can be designed to recalibrate the immune system for long-term maintenance of autoimmune remission.
Why invest in creating a modifiable drug framework?
Drug Target Review spoke with CUE Biopharma’s President and CSO to find out how and why they created the ImmunoSTAT platform and the ways it may benefit drug design in the future.
Could dolphins be viable models for human brain disorders?
Neuropathologic similarities between dolphins and humans suggest that the former could act as an effective model for the study of diseases such as Alzheimer’s. Professor Giovanni Di Guardo explains why dolphins could provide researchers with a new window into neurodegenerative conditons.
Novel molecules to adjust the circadian rhythm
A collaborative team of researchers has discovered two molecules that target the melatonin receptor, responsible for regulating the circadian rhythm. This article delves into their study and its therapeutic relevance for the body clock.
Discovering how drugs combat HIV and why resistance can occur
A group of researchers, led by Professor Zucai Suo, have revealed the mode of action of two HIV drugs and identified how resistance can develop, which they say could lead to improved drug design in the future.
ELRIG and the British Pharmacological Society: why form a strategic alliance?
Here, the benefits of collaborating in drug discovery are explored through the strategic alliance between ELRIG and the British Pharmacological Society.
Could the gut microbiome be the key to new antidepressant therapies?
Drug Target Review explores research that suggests the microbiome could be a therapeutic target for major depressive disorder and what treatment options are now in the pipeline as a result of this association.
Body-on-chip technology: resolving current limitations in drug discovery
Researchers have developed a new body-on-chip technology that can demonstrate the pharmacokinetics and pharmacodynamics of drugs in a pre-clinical setting without the need for animal testing.
